The UK and US have secured a landmark trade agreement that will maintain no tariffs on UK drug shipments being sold in the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has committed to increase expenditure on drugs through the NHS. This move ensures that duties on these key exports will remain at zero for a period of the next three years.
This development is in response to earlier warnings to dramatically increase import taxes on branded drug imports, with potential rates discussed as high as double the cost.
"This arrangement with the UK reinforces the international landscape for innovative medicines and establishes much-needed fairness to transatlantic pharmaceutical trade," an announcement said.
Commercial Significance
Drugs represent one of the Britain's biggest export categories to the America, which is clearly the biggest market for leading companies like GSK and AstraZeneca.
Statistics reveal that in the year leading up to September, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This amount accounted for nearly one-fifth of all goods exports in that timeframe.
"This deal safeguards employment, increases investment and facilitates the UK to emerge as a global hub for medical research," a minister remarked.
Key British Pledges
The pact entails several notable commitments from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new therapies to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to increase overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to control costs will be capped at fifteen percent. In the past, repayments were more than 20%.
Industry Background
The pact takes place against a protracted dispute between the sector and the ministers over drug pricing and NHS adoption.
This friction were heightened by assertions that US patients were paying several times more for the equivalent treatments than people in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been paused or scrapped, while major investments have been directed toward American operations.
The Science Minister publicly accepted that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had declined as a percentage of its resources over the previous ten-year period.
